Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2xCD3 BiTE
- Development stage
- Unknown
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HER2xCD3 BiTE is a target-specific bispecific T-cell engager (BiTE) platform designed to simultaneously bind human epidermal growth factor receptor 2 (HER2) on tumor cells and the CD3 subunit of the T-cell receptor complex on T cells. By physically bridging these two cell types, the bispecific antibody triggers T-cell activation, cytokine release, and directed cytotoxic activity against HER2-overexpressing cancer cells, independent of major histocompatibility complex (MHC) class I presentation. This therapeutic approach is being investigated for the treatment of various HER2-positive solid malignancies, including breast and gastric cancers, particularly to overcome resistance to conventional HER2-targeted therapies.
- Other names
- anti-HER2 x anti-CD3 BiTEanti-HER-2 x anti-CD3 BiTEanti-HER 2 x anti-CD3 BiTEHER2 x CD3 BiTEHER-2 x CD3 BiTEHER 2 x CD3 BiTEHER2-CD3 BiTEHER-2-CD3 BiTEHER 2-CD3 BiTEHER2/CD3 BiTE
02
Targets
CD3 (T-cell surface glycoprotein CD3)FCGRT (Neonatal crystallizable fragment receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on HER2xCD3 BiTE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2xCD3 BiTE.